Viracta Therapeutics, Inc. financial data

Symbol
VIRX on Nasdaq
Industry
Pharmaceutical Preparations
Location
2533 S Coast Hwy 101, Suite 210, Cardiff, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
SUNESIS PHARMACEUTICALS INC (to 3/2/2021)
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 143 % -80%
Debt-to-equity 215 %
Return On Equity -292 % -206%
Return On Assets -92.6 % -49.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 39.4M shares +2.17%
Common Stock, Shares, Outstanding 39.4M shares +2.17%
Entity Public Float 50.2M USD -65.5%
Common Stock, Value, Issued 4K USD 0%
Weighted Average Number of Shares Outstanding, Basic 39.4M shares +2.19%
Weighted Average Number of Shares Outstanding, Diluted 39.4M shares +2.19%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 15.4M USD -37.4%
Operating Income (Loss) -49.5M USD +8.85%
Net Income (Loss) Attributable to Parent -45.3M USD +14.1%
Earnings Per Share, Basic -1.16 USD/shares +15.9%
Earnings Per Share, Diluted -1.16 USD/shares +40.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 14M USD -2.18%
Cash, Cash Equivalents, and Short-term Investments 30M USD -58.8%
Assets, Current 31.1M USD -58.3%
Property, Plant and Equipment, Net 135K USD -54.4%
Operating Lease, Right-of-Use Asset 71K USD -84.6%
Other Assets, Noncurrent 44K USD -97.2%
Assets 31.3M USD -59.2%
Accounts Payable, Current 1.29M USD -60.2%
Employee-related Liabilities, Current 565K USD -68.5%
Accrued Liabilities, Current 8.55M USD +17.2%
Liabilities, Current 28.7M USD +88.3%
Operating Lease, Liability, Noncurrent 73K USD +2.82%
Liabilities 28.7M USD -20.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax -5K USD +95.7%
Retained Earnings (Accumulated Deficit) -285M USD -18.9%
Stockholders' Equity Attributable to Parent 2.67M USD -93.5%
Liabilities and Equity 31.3M USD -59.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.85M USD +30.8%
Net Cash Provided by (Used in) Financing Activities -6.6M USD -141%
Net Cash Provided by (Used in) Investing Activities 14.2M USD
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 39.4M shares +2.17%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 14M USD -2.18%
Interest Paid, Excluding Capitalized Interest, Operating Activities 851K USD +47%
Deferred Tax Assets, Valuation Allowance 73.2M USD +20.6%
Deferred Tax Assets, Gross 73.3M USD +20.5%
Operating Lease, Liability 73K USD -84.6%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -45.2M USD +14.5%
Lessee, Operating Lease, Liability, to be Paid 73K USD -85.7%
Operating Lease, Liability, Current 73K USD -81.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 294K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 110K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.15 pure +87.5%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 0 USD -100%
Preferred Stock, Shares Issued 10.2K shares 0%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 6.78M USD +17.3%
Operating Lease, Payments 209K USD -66.7%
Additional Paid in Capital 282M USD +2.59%
Preferred Stock, Shares Outstanding 10.2K shares 0%
Depreciation, Depletion and Amortization 110K USD -9.84%
Share-based Payment Arrangement, Expense 6.77M USD -51.3%
Interest Expense 3.46M USD +62.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%